Graft-vs-host disease (GVHD) is a common, life-threatening complication of bone marrow transplantation that frequently involves the gastrointestinal tract. Since symptoms are typically nonspecific, radiologic examination is often performed to reach a diagnosis. To the best of our knowledge, this is the first reported radiologic description of a case of rectal involvement as the first manifestation of GVHD. The differential diagnosis of segmental rectal wall thickening in a patient following bone marrow transplantation should include GVHD.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Post hematopoietic stem cell transplant (HSCT) outcomes in pediatric intensive care unit, experience from a referral center for cellular therapy and hematopoietic stem cell transplantation.
Hematol Oncol Stem Cell Ther
January 2025
Pediatric Critical Care consultant, Pediatric Critical Care department, Ad Diriyah hospital, Riyadh, Saudi Arabia.
Background: Patients who underwent hematopoietic stem cell transplantation (HSCT) are considered at high risk for pediatric intensive care unit (PICU) admission. Therefore, this study aimed to assess outcomes and mortality-related risk factors among pediatric HSCT recipients admitted to the PICU.
Methods: This retrospective cohort study was conducted at a Saudi Arabian tertiary care center and involved pediatric patients (aged 4 weeks to 14 years) who underwent HSCTs between January 2015 and December 2019 and were admitted to the PICU.
Low incidence of primary graft failure with bendamustine, fludarabine, and busulfan conditioning prior to haploidentical allogeneic hematopoietic cell transplantation.
Hematol Oncol Stem Cell Ther
January 2025
R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, State Medical University Named I.P. Pavlov, Saint-Petersburg, Russian Federation.
The outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) have improved with the implication of new in vivo and ex vivo graft-versus-host disease (GVHD) prophylaxis regimens. However, primary graft failure is still reported more frequently in haplo-HCT compared to a matched donor HCT. We conducted a pilot study (NCT04942730) to evaluate the impact of adding bendamustine to fludarabine and busulfan conditioning on engraftment after haplo-HCT.
View Article and Find Full Text PDFTransfusion-associated graft-versus-host disease (TA-GVHD) and graft-versus-host disease (GVHD): Pathophysiology and management (contrasted and compared).
Hematol Oncol Stem Cell Ther
January 2025
Hematology Laboratory-Blood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Transfusion of blood products is a common lifesaving medical procedure in clinical practice. However, it poses the risk of potential adverse reactions for the recipient. Transfusion-associated graft-versus-host-disease (TA-GVHD) is a rare adverse event, fatal in >90% of cases.
View Article and Find Full Text PDFBackground: The role of fiberoptic bronchoscopy (FOB) in the management of patients presenting with pulmonary infiltrates after hematopoietic stem cell transplant (HSCT) remains unclear. We aimed to evaluate the diagnostic value and safety of FOB at our center.
Methods: This retrospective study included all patients with post-HSCT pulmonary infiltrates who underwent FOB between 2016 and 2019.
Impact of Obesity on GVHD in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Hematologic Malignancies.
Transplant Cell Ther
January 2025
Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:
Background: The relationship between obesity and graft-versus-host disease (GVHD) has been studied in both pre-clinical and clinical studies with varying results.
Objectives: We aimed to investigate the impact of obesity, as measured by body mass index (BMI), on the incidence, severity, and response to therapy of GVHD in a contemporary cohort.
Study Design: We conducted a retrospective study of patients undergoing allogeneic hematopoietic cell transplant (HCT) for acute myelogenous leukemia and myelodysplastic syndrome between January 2010 and December 2021 at the Cleveland Clinic.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!